Why GLP-1s Make You Tired — and What to Do About It

The fatigue is real. Energy cratering after a GLP-1 medication starts is not imagined. Clinical trials report fatigue in the single digits to low teens, but real-world reports show more texture: day-after-injection crashes, week-3 or week-4 titration walls, cold hands, insomnia, low drive, and a second fatigue wall months later.

The body is doing hard metabolic work. It is eating less, moving stored fat, changing gut speed, and adapting to a drug that also touches appetite and reward circuits. The compound changes the failure mode. A semaglutide user with low drive sits in a different place than a retatrutide user with elevated resting heart rate, chills, and brain fog.

GLP-1 Fatigue at a Glance

GLP-1 fatigue differs by compound because each drug puts pressure on a different part of the system. Semaglutide is the clean GLP-1-only version: appetite suppression, slower stomach emptying, and more risk that food and protein fall too low. Tirzepatide adds GIP, so the same weight-loss goal is split across two signals and often feels smoother. Retatrutide adds glucagon, which makes the liver burn harder and adds heart-rate and temperature signals as dose climbs.

Tirzepatide spreads the work. Semaglutide runs mostly through GLP-1 appetite pressure. Tirzepatide adds a GIP signal in fat tissue, so it can produce more weight loss with less GLP-1 burden than semaglutide.¹ That is why many users describe tirzepatide as smoother even when the scale is moving faster.

Retatrutide adds demand on both sides. The glucagon arm makes the liver oxidize its own fat and helps offset the fall in energy expenditure that normally accompanies weight loss, while the GLP-1 component suppresses appetite — more fuel burned than without that protection, against less coming in.

The clearest direct cardiovascular signal is not theoretical: retatrutide raises resting heart rate.¹¹ Semaglutide and tirzepatide also raise heart rate modestly; retatrutide’s distinguishing feature is the larger, dose-scaling signal associated with its glucagon arm. That signal is a monitoring cost, not a meaningful explanation for the calorie deficit or fatigue by itself.

Semaglutide has a less favorable body-composition anchor. It can work beautifully, but if appetite suppression outruns protein, training, and recovery, lean mass pays. Its main non-diabetic DXA data showed roughly 38-39% of weight loss came from lean mass². Tirzepatide’s pooled non-diabetic DXA anchor is closer to 25%³. That cross-trial difference matters to the support plan; neither DXA substudy measured fatigue or functional capacity.

Why GLP-1 Drugs Cause Fatigue

GLP-1 fatigue comes from the body running a larger energy deficit than it can sustain, combined with the drug acting directly on the brain’s motivation and energy regulation systems. Which mechanisms hit hardest depends on the compound, the dose, and how aggressively intake is restricted. These aren’t separate problems — they reinforce each other, and the two categories map to different fixes.

The body does not have enough usable fuel

Four mechanisms compound here, and each one makes the others worse.

Fat burning needs enough energy capacity. NAD+ is one of the cofactors cells use to turn mobilized fat into usable energy.⁴ Retatrutide’s measured hepatic-fat-oxidation signal makes that redox demand mechanistically relevant.¹⁵ Whether NAD+ capacity actually becomes the bottleneck—and whether injected NAD+ corrects it—remains the protocol hypothesis rather than a measured Retatrutide fatigue mechanism.

Muscle breaks down alongside fat. Without adequate protein and resistance training, the body catabolizes muscle for amino acids during a deficit. How much depends on the compound — semaglutide’s STEP-1 DXA lean fraction was roughly 38-39%, while tirzepatide’s SURMOUNT-1 DXA lean fraction was about 25% (see comparison table above). Neither DXA substudy measured fatigue. When declining lean mass is accompanied by falling strength or exercise tolerance, the symptom is more likely to feel like weakness than sleepiness.

Nutrient intake and absorption can drop. Delayed gastric emptying changes how meals feel, and appetite suppression often leads users to skip the foods that carry iron, B12, sodium, potassium, and complete protein.⁵ Semaglutide’s higher gallbladder signal adds another layer because bile problems can mimic or worsen nausea, malabsorption, and fatigue⁶.

What makes GLP-1 fatigue different from ordinary dieting fatigue: the deficit is drug-enforced, persistent, and often more aggressive than a voluntary diet. "Eating a little more" isn’t available when the drug suppresses appetite at a neurological level.

The brain is responding to the drug directly

Two distinct CNS effects operate here, and they feel different from the metabolic fatigue above.

Drive can flatten. GLP-1 signaling touches reward and motivation circuits. Some users do not feel depressed; they just stop feeling the pull to initiate food, workouts, sex, social plans, or projects. This is most common in semaglutide-style GLP-1-heavy fatigue. When the enjoyment is still there once an activity is underway but getting started feels strangely muted, the dose is pressing hard on reward signaling.

Cold hands, brain fog, and sluggishness: the system is conserving heat. Heat production in brown fat is gated locally by DIO2, an enzyme that amplifies thyroid hormone three- to four-fold inside the tissue. A sustained deficit suppresses the thyroid axis on its own — 72 hours of fasting cuts T3 by roughly 30% — and on retatrutide two further effects push the same direction: FGF21 falls dose-dependently to −65.7% at 8 mg, and FGF21 is what supports DIO2, while continuous glucagon engagement lowers T3 and raises reverse-T3 with TSH unchanged.

That gives a specific test rather than a general referral. The thyroid route reads as Free T3 down, reverse T3 up, TSH normal, with cold skin and a widened gap between core and skin temperature. A separate route — GLP-1 raising skin and leg blood flow, shedding heat where cold is felt — reads as an intact thyroid panel with skin that is warm to the touch but feels cold, and a narrowed gap. Because TSH does not move on the glucagon route, a TSH-first screen reads normal and stops; Free T3 and reverse T3 have to be named on the order. Persistent sluggishness, cold extremities, and brain fog that sleep does not fix are worth that panel.

How to Fix GLP-1 Fatigue

Most GLP-1 fatigue resolves with the right combination of dose adjustment, adequate protein, and targeted supplementation. The specific fix depends on the type of fatigue in play — motivational flatness, physical exhaustion, GI-driven malnutrition, or metabolic wall — and most people present with more than one.

The patterns map as follows:

What each pattern responds to:

• Low motivation, flat affect: Split dose frequency (lower peaks = less suppression); exercise helps acutely; resolves as brain adapts
• Physical exhaustion, weak legs: Protein 1.2+ g/kg, resistance training, caloric floor 1,200+ cal
• Cold extremities, brain fog: clinical thyroid evaluation guided by history, symptoms, and current medication
• Nausea, can’t eat enough, bloating: Smaller frequent meals, electrolytes, ferritin/B12/iron panel
• Energy wall at months 3-6: Labs, recovery audit, consider mito-stack protocol

The foundation everyone should start with

These interventions address the root causes of GLP-1 fatigue regardless of compound. The dose already in use is the starting point. Active symptoms are the signal to hold the current step rather than escalate into fatigue.

Dose hold before dose increase. Active fatigue, nausea, constipation, reflux, insomnia, chills, appetite collapse, or elevated resting heart rate marks a body that hasn’t caught up to the current step; in the trials, four weeks is the minimum adaptation window before the next increase, not a command to escalate.

Dose frequency and peak-sensitive users. Weekly injections create a peak-and-trough curve. Fatigue that is worst in the first 1-3 days after injection and eases near the end of the week tracks peak concentration, and splitting the same weekly total lowers peaks and smooths the curve. This is a tolerability lever, not a change to the weekly total. The GLP-1 dosing calculator visualizes the curve.

Dose titration: slow and steady. Fatigue peaks during dose escalation (weeks 1-16 across titration) and resolves within 4-12 weeks at each stable dose. Less than 1% of participants in STEP trials discontinued due to fatigue alone². When exhaustion is the complaint, the first question is whether titration is still underway. The trial ladders ran a full 4+ weeks at each dose before the next step, and not every cohort reached the maximum dose.

Protein: at least 1.2 g/kg body weight daily where body composition matters.⁸ Each meal needs enough complete protein to signal that muscle is still needed. In practice that runs 30-50 g protein at 3-4 feedings, plus shakes or essential amino acids on low-appetite days.

Resistance training: 2-4 sessions per week. Lean mass loss is a consequence of inadequate protein plus sedentary behavior during a caloric deficit — it is not an inevitable side effect of the drug. A 2025 case series documented patients who gained lean mass while on GLP-1 therapy by combining resistance training (≥3x/week) with high protein (1.6-2.3 g/kg/day) — one patient lost only 8.7% of total weight as lean mass, far below the DXA-anchor range of concern: ~25% for tirzepatide to ~38-39% for semaglutide.¹² Resistance training is the strongest stimulus for muscle preservation. It also supplies a short-term drive signal, which counts when the drug makes starting a workout feel harder.

Hydration: 2-3 liters daily, between meals. GLP-1 drugs create four separate dehydration mechanisms: blunted thirst perception (one trial showed a 17% reduction in daily fluid intake — nearly 500 mL less per day — because the drug suppresses the drive to drink), delayed gastric emptying (water sits in the stomach longer), GI fluid losses (nausea, vomiting, diarrhea), and renal natriuresis (the kidneys excrete more sodium, pulling water with it).¹³ Electrolytes matter more than volume — sodium specifically, because GLP-1-induced natriuresis depletes it independent of intake.

Sleep: 7-9 hours. NAD+ recycling is circadian-dependent. Short sleep accelerates the depletion that drives the months 3-6 wall.

Targeted support — test and address

When the foundation is solid and fatigue persists, these targeted interventions address specific mechanisms.

CoQ10 (ubiquinol): 100-300mg daily. A meta-analysis of 13 randomized controlled trials (N=1,126) found significant fatigue reduction with CoQ10 supplementation (Hedges' g = -0.398, p=0.001)⁹. The strongest effects were in statin-induced fatigue, fibromyalgia, and chronic fatigue syndrome — all conditions involving mitochondrial energy production strain, which overlaps mechanistically with GLP-1 fatigue. Ubiquinol (the reduced form) absorbs better than ubiquinone.

L-Carnitine injectable (500mg-1g IM) or ALCAR (1-2g oral). Carnitine moves fatty acids into mitochondria for burning. GLP-1 therapy forces more fat burning than normal, which can deplete carnitine faster than it is replenished. Injectable L-carnitine (IM, 500mg-1g) bypasses both the oral bioavailability problem and the GI issues GLP-1 users already experience — oral L-carnitine has only ~14% absorption, and gut bacteria convert the unabsorbed remainder to TMAO (trimethylamine N-oxide), a cardiovascular risk biomarker. On the oral route, ALCAR (acetyl-L-carnitine, 1-2g/day) absorbs better than regular L-carnitine and reduces the TMAO concern.

Electrolytes: sodium, potassium, magnesium. Sodium is critical — GLP-1-induced natriuresis depletes it independently of dietary intake. Magnesium (200-400mg glycinate or threonate) supports both energy production and sleep quality.

Lab work, reviewed with a clinician. The monitoring rhythm in this layer is a baseline before starting a GLP-1, then rechecks at 3 months and 6 months: ferritin, B12, vitamin D, fasting glucose / insulin context where relevant, and thyroid testing when history or symptoms justify it. No single retatrutide-specific thyroid marker has been established.

Mitochondrial support for the months 3-6 wall

When fatigue returns or plateaus after months of initial improvement, energy production itself may be the bottleneck. NAD+ is part of the cofactor layer for turning mobilized fat into usable energy⁴. Among injectable NAD+ routes, IM is the common peptide-user route; SubQ works split into smaller doses, since larger SubQ pushes can welt or irritate. A small 2026 double-blind trial (45 people, nine arms) gave 100 mg NAD+ by IM, IV, and SC over three days and found all three tolerated, which is the first controlled human read on these routes — it measured tolerability rather than how much reaches tissue. Oral precursors such as NR or NMN are a different route with different reliability. For deeper mitochondrial support, the mito-stack protocol covers the full approach. For retatrutide users specifically, the retatrutide + NAD+ protocol addresses the glucagon-specific fatigue hypothesis.

The Thresholds That Move This to Clinical Evaluation

The patterns that warrant clinical evaluation:

• New thyroid-test abnormalities interpreted with symptoms and medication history — no single retatrutide-specific marker has been established
• Fatigue consistently below 5/10 despite foundational and targeted interventions held for 4+ weeks
• Severe GI symptoms blocking adequate nutrition — protein intake too low or food not staying down
• Cold intolerance + severe fatigue + depressed mood together — the thyroid-evaluation cluster, especially on retatrutide
• Concurrent levothyroxine or other thyroid medication. The relevant check is TSH at 6-8 weeks after a GLP-1 starts, not only at the annual interval. Weight loss can leave an existing dose too high — a study of hypothyroid patients on tirzepatide found 29% had TSH suppressed below normal range within 6 weeks. Oral semaglutide specifically increases levothyroxine absorption by 33% through delayed gastric emptying.¹⁴ Either scenario produces hyperthyroid symptoms (palpitations, anxiety, insomnia, tremor) that look like GLP-1 fatigue but trace to a now-excessive thyroid-medication dose.

On a compound switch: where semaglutide fatigue is primarily motivational (flat affect, no drive), tirzepatide’s lower GLP-1 potency (0.2x vs 1x) carries less reward-pathway blunting at comparable weight-loss efficacy.

Is Fatigue Associated With Semaglutide? (Ozempic, Wegovy)

Yes. Fatigue was reported in approximately 11% of participants at the 2.4 mg obesity dose versus 5% on placebo in the Wegovy program.² Fatigue was reported below 1% in parts of the Ozempic diabetes program, but those are different trials, populations, capture systems, and durations. The cross-program contrast is compatible with a dose contribution; it is not a clean randomized dose-response estimate.

The STEP trial program provides the most detailed fatigue data of any GLP-1:

• STEP-1: ~11% fatigue at 2.4mg
• STEP-3: 12.8% — the highest rate, in the trial combining semaglutide with intensive behavioral therapy (suggesting that aggressive lifestyle changes compound drug-induced fatigue)
• STEP-8: 9.5% semaglutide vs 4.7% liraglutide vs 0% placebo — direct evidence that semaglutide causes more fatigue than the older GLP-1

A pooled meta-analysis of 50 semaglutide trials found a relative risk of 4.23 for asthenia (95% CI 1.34-13.36) with I²=0%.¹⁰ That means the meta-analysis did not detect between-study heterogeneity at its available resolution; it does not mean every individual trial produced the same result. FAERS pharmacovigilance data shows a reporting disproportionality signal for injectable semaglutide but not oral semaglutide; that difference is hypothesis-generating and does not establish a dose or CNS-penetration mechanism.

As covered in the comparison above, semaglutide can present with physical weakness, motivational flatness, or both. The DXA substudy establishes a lean-mass change, not fatigue causality; the reward-circuit model supplies a plausible mechanism for low drive, not a prevalence estimate for a combined phenotype.⁷

Fatigue commonly clusters during titration and often improves after a stable-dose hold. Less than 1% of STEP participants discontinued specifically due to fatigue. Gallbladder and biliary risk is elevated across the GLP-1 class and is worth monitoring separately — bile dysfunction can cause fatigue, malabsorption, and nausea that mimic other GLP-1 side effects.⁶

For complete semaglutide dosing, results data, and side effect management, see the full semaglutide guide.

Is Fatigue Associated With Tirzepatide? (Mounjaro, Zepbound)

Tirzepatide is often smoother than semaglutide, but it is not fatigue-proof. Its GIP-forward design splits the metabolic work across two signals, and its GLP-1 burden per unit of weight loss is lower. Fatigue still appears when appetite suppression gets ahead of protein, hydration, bowel function, sleep, and training.

SURMOUNT trial fatigue rates show a clear dose-response: 5% at 5mg, 6% at 10mg, 7% at 15mg versus 3% on placebo. The European Medicines Agency classifies fatigue as "Common" (1-10%) for type 2 diabetes patients and escalates it to "Very Common" (10%+) in the obesity population, reflecting the deeper caloric deficits at higher doses.

The reason tirzepatide often feels better despite more weight loss comes back to the GIP receptor. Fat tissue is part of the signaling target, so the drug is not relying only on GLP-1 appetite suppression. Compare that with semaglutide, where the result leans more heavily on eating less, and retatrutide, where the glucagon arm adds liver and heart-rate demand.

Lower GLP-1 receptor pressure means less reward-pathway suppression for many users. Some preclinical work suggests GIP may reduce nausea, but tirzepatide’s own clinical advantage is better explained by lower GLP-1 burden per unit of weight loss. Keep the anti-nausea claim as a hypothesis, not a proven reason.

Body-composition data supports a more fat-weighted loss pattern: the pooled tirzepatide DXA substudy shows approximately 25% of measured fat-plus-lean loss was lean mass, compared with roughly 38-39% in the separate semaglutide DXA anchor³. The studies did not measure whether that difference translated into better function or less fatigue.

One practical nuance: tirzepatide can still produce fatigue in lower-weight users or in users who lose appetite too completely. Falling protein, building constipation, or dropping training output marks a body the support layer or a dose hold addresses before the next step, not one to climb through.

For complete tirzepatide dosing and comparison data, see the full tirzepatide guide.

How Does Retatrutide-Associated Fatigue Compare?

Retatrutide fatigue is the least forgiving because it can combine appetite suppression with glucagon-driven energy demand. It is not just "stronger GLP-1." At low dose, reta is GIP-forward; as dose climbs, GLP-1 satiety and glucagon heart-rate / liver-fat effects become more relevant.

The critical variable is titration speed. Moving too quickly leaves nausea, appetite collapse, elevated resting heart rate, chills, insomnia, fatigue, or skin sensitivity persisting instead of fading. The retatrutide dose-logic threshold is plain: each step holds at least 4 weeks, and active symptoms mark a step the body hasn’t cleared rather than one to climb through.

The glucagon differentiator matters to retatrutide fatigue, but the human boundary is specific. The drug raises hepatic fat oxidation and is expected to protect against the fall in energy expenditure that accompanies weight loss. Human retatrutide resting energy expenditure has not been directly measured, so the copy cannot turn that mechanism into a quantified above-baseline lift.

The retatrutide trials measured no thyroid-axis endpoints, which is why the panel is worth taking rather than inferring. The mechanism predicts a specific pattern — Free T3 down and reverse T3 up with TSH unchanged — and because TSH is the part that does not move, the order has to name Free T3 and reverse T3 or the screen comes back falsely reassuring.

All three contributing routes scale with dose, so the expectation is that cold intolerance climbs through the dose range rather than peaking somewhere in the middle. Glucagon engagement rises continuously, the energy deficit deepens, and both push the same direction on the same node.

Heart-rate elevation tracks the glucagon arm and phenotype: the obese Phase 2 cohort read +0.7 bpm at 1 mg on ambulatory monitoring, while the lean Phase 1 cohort averaged +10.3 bpm at the same dose — so a leaner user should not calibrate against the trial figure.

Red flag combination: cold intolerance + severe persistent fatigue + depressed mood is a thyroid-evaluation cluster. The panel worth ordering includes Free T3 and reverse T3 alongside TSH and Free T4, because the drug route moves T3 and reverse T3 while leaving TSH normal — a TSH-only screen will miss it. Clinical history and current medication still frame the interpretation.

Retatrutide is still investigational. That status is development context, not a simple safety verdict. For the specific NAD+ protocol designed around retatrutide’s glucagon-driven energy demand, see the retatrutide + NAD+ protocol. For general compound information, see the retatrutide guide.

Does GLP-1 Fatigue Go Away?

For most people, yes. GLP-1 fatigue follows a predictable pattern: it peaks during dose titration, improves as the body adapts, and resolves for the majority of users who maintain stable doses with adequate nutrition.

Weeks 1-16 (titration phase). Fatigue peaks with each dose increase. This is when most people feel worst. Every step up — 0.25 to 0.5, 0.5 to 1.0, and so on — restarts a 2-4 week adaptation window. The body hasn’t failed; it’s recalibrating to a new level of appetite suppression and metabolic demand.

Weeks 4-12 at stable dose. Energy normalizes for most users. The brain adapts to altered dopamine signaling, the body adjusts metabolic rate to the new caloric intake, and GI symptoms that reduce nutrient absorption typically improve. This is when people say "it got better on its own."

The months 3-6 wall. A second wave of fatigue appears in a subset of users and is distinct from titration fatigue. It usually does not mean the drug has stopped working. It often reflects sustained caloric restriction plus accumulated gaps: lower recovery capacity, possible mitochondrial cofactor strain, and micronutrient deficits such as iron, B12, or vitamin D. The practical response is not more caffeine. It is lab work, recovery repair, and targeted energy support when the bottleneck fits.

If fatigue does not resolve: persistent fatigue beyond 12 weeks at a stable dose, despite adequate protein and foundational interventions, warrants clinical evaluation. The workup that fits this pattern includes thyroid testing based on history and symptoms, ferritin and B12 (nutrient depletion), and a read on whether a compound switch — or dose reduction — is the next lever.

Less than 1% of participants across all major GLP-1 trials discontinued due to fatigue alone². The fatigue is real, but for the vast majority, it’s temporary.

Frequently Asked Questions

Related Topics

• Semaglutide Guide
• Tirzepatide Guide
• Retatrutide Guide
• Retatrutide + NAD+ Protocol
• Mito Stack Protocol
• NAD+ Guide
• BPC-157 Guide (for GI support)
• GLP-1 Compound Comparison
• GLP-1 Dosing Optimizer — split weekly doses to smooth plasma levels
• Semaglutide Dosing Calculator
• Tirzepatide Dosing Calculator
• Retatrutide Dosing Calculator
• Preserving Lean Mass on GLP-1s
• Stopping GLP-1s — taper protocol, what actually happens, how to hold the weight
• Peptide Calculator

References

¹ Xinxin Yu et al. GIP-receptor activation induces futile calcium cycling in white adipocytes in an inducible mouse model. Cell Metabolism. 2025. DOI: 10.1016/j.cmet.2024.11.003

² Wilding JPH, Batterham RL, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183. Body composition: Wilding JPH, et al. Exploratory STEP 1 analysis. J Endocr Soc. 2021;5(Suppl 1):A16-A17. DOI: 10.1210/jendso/bvab048

³ Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes, Obesity and Metabolism. 2025. DOI: 10.1111/dom.16275

⁴ Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2020. PMC7963035.

⁵ Nutrient depletion during GLP-1 therapy — ferritin, B12, vitamin D, sodium, and protein intake can become limiting when appetite and gastric motility change. Use lab monitoring rather than assuming fatigue is purely behavioral.

⁶ He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Internal Medicine. 2022.

⁷ Reward-circuit framing — GLP-1 signaling can reduce drive and food seeking through central appetite and reward pathways. Use as mechanism context, not as a stand-alone diagnosis.

⁸ Protein during incretin therapy — practical floor is at least 1.2 g/kg/day when lean-mass preservation matters, distributed across protein-forward meals.

⁹ Meta-analysis of Coenzyme Q10 for fatigue reduction. 13 RCTs, N=1,126. Hedges' g = -0.398 (p=0.001). Strongest effects in mitochondrial-mediated fatigue conditions.

¹⁰ Sillassen L, et al. Systematic review and meta-analysis of 50 semaglutide trials (>54,000 participants). BMC Medicine. 2025. Asthenia RR 4.23 (95% CI 1.34-13.36), I²=0%. PMC12642075

¹¹ Jastreboff AM, Kaplan LM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2301972

¹² Trexler ET, et al. Lean mass gains during GLP-1 RA therapy with resistance training + high protein (1.6-2.3 g/kg FFM/day). SAGE Open Medical Case Reports. 2025. PMC12536186

¹³ Winzeler B, et al. GLP-1 RA reduces fluid intake by 490 mL/day (17%) and thirst perception on fMRI. J Endocrine Society. 2021. PMC8090681

¹⁴ Ahmed et al. TSH suppression in hypothyroid patients on tirzepatide: 29% (5/17) suppressed below normal at 6 weeks. Diabetes Obes Metab. 2023. DOI: 10.1111/dom.15279. Oral semaglutide + levothyroxine AUC increase of 33%: Wegovy FDA label pharmacokinetics section.

¹⁵ Retatrutide hepatic oxidation — Sanyal AJ, et al. measured liver-fat and β-hydroxybutyrate changes: 10.1038/s41591-024-03018-2. Pearson MJ, et al. measured the accompanying lipid and metabolite fingerprint: 10.1210/clinem/dgag201. These carry the hepatic FAO signal; they do not test NAD+ supplementation for fatigue.

This article is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription pharmaceuticals — dosing changes, compound switches, and supplementation strategies should be discussed with your prescribing physician. The interventions described here range from well-established (protein, resistance training) to mechanistically supported but not yet validated by randomized controlled trials for GLP-1 fatigue specifically (NAD+ precursors, mitochondrial peptides). Evidence levels are separated throughout.